Tarsus Pharmaceuticals, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Tarsus Pharmaceuticals, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Tarsus Pharmaceuticals, Inc. do? Business model and key facts
Get the full picture of Tarsus Pharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 370
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Stocks related to Tarsus Pharmaceuticals, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Tarsus Pharmaceuticals, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Tarsus Pharmaceuticals, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
